Loading
Life sciences · Journal article
Pharmaceutical Biology · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a validated UPLC-MS/MS bioanalytical method for simultaneous quantification of 12 kratom alkaloids and 5 mitragynine metabolites in human plasma, developed according to FDA guidelines. The method was applied to plasma samples from a small clinical trial of regular kratom users, demonstrating rapid absorption (peak concentrations 1–2 h post-dose) and identification of major circulating alkaloids and metabolites, but provides no efficacy, safety, or clinical outcome data.
Bioanalytical method validation study (UPLC-MS/MS) with descriptive clinical application. Four regular kratom users; further demographic and eligibility details not provided in the source text.. Intervention: Oral kratom product administration. Not explicitly stated; authors affiliated with University of Florida and Johns Hopkins School of Medicine (Baltimore, MD)..
Method linear over concentration range 1–250 ng/mL Upon oral kratom administration, most alkaloids absorbed quickly with peak plasma concentrations within 1–2 h post-dose Major circulating alkaloids: mitragynine, speciociliatine, mitraciliatine, isopaynantheine, and paynantheine
Clinical application limited to descriptive pharmacokinetics in 4 users; no comparator group, randomization, or clinical endpoints reported.
This method enables standardized pharmacokinetic profiling of kratom alkaloids and metabolites in clinical research, supporting future controlled trials and safety assessment. However, the current report provides no clinical outcomes or efficacy/safety signals and should be regarded as a technical contribution pending application to adequately powered clinical studies.
This is a bioanalytical method development and validation study applied to a small clinical pharmacokinetic sample from regular kratom users, providing first systematic multiplex quantification but lacking efficacy or safety endpoints.
As stated by the source record.
Quoted from the source exactly as published.
This method enables standardized pharmacokinetic profiling of kratom alkaloids and metabolites in clinical research, supporting future controlled trials and safety assessment. However, the current report provides no clinical outcomes or efficacy/safety signals and should be regarded as a technical contribution pending application to adequately powered clinical studies.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Context. Mitragyna speciosa Korth, commonly known as kratom, has been used traditionally in Southeast Asia by chewing fresh leaves and brewing decoctions (tea) for its stimulant and sedative-like properties. Despite its widespread use, controlled clinical trials are limited and have monitored mitragynine only or a few other major alkaloids and metabolites.Objective. The objective of the study was to develop and validate an ultra performance liquid chromatography-mass spectrometry (UPLC-MS/MS) method for the simultaneous quantification of 12 kratom alkaloids along with 5 metabolites of mitragynine in human plasma.Materials and methods. A sensitive UPLC-MS/MS based bioanalytical method for the simultaneous quantification of kratom alkaloids, including mitragynine, speciogynine, speciociliatine, mitraciliatine, paynantheine, isopaynantheine, corynantheidine, corynoxine-A, corynoxine-B, mitraphylline, speciofoline, and ajmalicine, along with five metabolites of mitragynine, 7-hydroxymitragynine, 9-hydroxycorynantheidine, mitragynine 16-carboxylic acid, mitragynine pseudoindoxyl, and 3-dehydromitragynine in human plasma was developed and validated following FDA guidelines. Chemically unstable metabolites, 7-hydroxymitragynine and 9-hydroxycorynantheidine, were stabilized in human plasma. The bioanalytical method was further used for the analysis of plasma samples collected during a clinical trial involving four regular kratom users.Results. The method was linear over the concentration range of 1-250 ng/mL. A simple protein precipitation method was used to extract analytes. Upon oral administration of kratom products, most of the alkaloids were absorbed quickly and showed peak plasma concentrations within 1-2 h post-dose.Discussion and conclusions. Mitragynine, speciociliatine, mitraciliatine, isopaynantheine, and paynantheine are major circulating alkaloids, with mitragynine 16-carboxylic acid and 9-hydroxycorynantheidine being the major circulating metabolites of mitragynine in plasma upon kratom oral administration.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.